Sangamo Biosciences reported $-46455000 in EBITDA for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acceleron Pharma XLRN:US $ -62.63M 0.05M
Alnylam Pharmaceuticals ALNY:US $ -134.35M 39.3M
Amgen AMGN:US $ 3188M 218M
Avrobio Inc AVRO:US $ -31076000 4.48M
Bayer BAYN:GR € 3035M 1119M
Biogen BIIB:US $ 1147.6M 41.7M
Biomarin Pharmaceutical BMRN:US $ 41.16M 14.24M
Bluebird Bio BLUE:US $ -234.8M 9.32M
Gilead Sciences GILD:US $ 2816M 669M
GlaxoSmithKline GSK:LN 2626M 584M
Intercept Pharmaceuticals ICPT:US $ 1.39M 29.71M
IONIS PHARMACEUT IONS:US $ -68.34M 19.17M
Johnson & Johnson JNJ:US $ 8103M 786M
Karyopharm Therapeutics KPTI:US $ -48819000 3.32M
Novartis NOVN:VX SF 4772M 423M
Omeros OMER:US $ -23661000 6.56M
Pfizer PFE:US $ 7593M 610M
Sangamo Biosciences SGMO:US $ -46.46M 2.03M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M
Ultragenyx Pharmaceutical RARE:US $ -79.66M 23.55M
Vertex Pharmaceuticals VRTX:US $ -5.12M 917.88M
Ziopharm Oncology ZIOP:US $ -21.96M 0.94M